FOLFIRINOX therapy was associated with the longest OS for all patients regardless of the tumor KRAS mutation status, with a median OS of 12.2 (95% CI, 11.5-13.4) months for KRAS mutations and 18.5 (95% CI, 14.4-22.1) months for KRAS WT. The gene discussed is KRAS; the disease is neoplasm.